|
1
|
Barlesi F, Mazieres J, Merlio JP,
Debieuvre D, Mosser J, Lena H, Ouafik L, Besse B, Rouquette I,
Westeel V, et al: Routine molecular profiling of patients with
advanced non-small-cell lung cancer: results of a 1-year nationwide
programme of the French cooperative thoracic intergroup (IFCT).
Lancet. 387:1415–1426. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tian HX, Zhang XC, Yang JJ, Guo WB, Chen
ZH, Wang Z and Wu YL: Clinical characteristics and sequence
complexity of anaplastic lymphoma kinase gene fusions in Chinese
lung cancer patients. Lung Cancer. 114:90–95. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wu YL, Dziadziuszko R, Ahn JS, Barlesi F,
Nishio M, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, et al:
Alectinib in resected ALK-positive non-small-cell lung cancer. N
Engl J Med. 390:1265–1276. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zou Z, Xing P, Hao X, Wang Y, Song X, Shan
L, Zhang C, Liu Z, Ma K, Dong G and Li J: Intracranial efficacy of
alectinib in ALK-positive NSCLC patients with CNS metastases-a
multicenter retrospective study. BMC Med. 20:122022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li J, Zhang B, Zhang Y, Xu F, Zhang Z,
Shao L, Yan C, Ulivi P, Denis MG, Christopoulos P, et al:
Concomitant mutation status of ALK-rearranged non-small cell lung
cancers and its prognostic impact on patients treated with
crizotinib. Transl Lung Cancer Res. 10:1525–1535. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang L, Xiao P, Meng F and Zhong D:
STRN-ALK fusion in lung adenocarcinoma with brain metastasis
responded well to ensartinib: A case report. Curr Oncol.
29:6749–6753. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Detterbeck FC, Chansky K, Groome P,
Bolejack V, Crowley J, Shemanski L, Kennedy C, Krasnik M, Peake M,
Rami-Porta R, et al: The IASLC lung cancer staging project:
Methodology and validation used in the development of proposals for
revision of the stage classification of NSCLC in the forthcoming
(eighth) edition of the TNM classification of lung cancer. J Thorac
Oncol. 11:1433–1446. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lin JJ, Riely GJ and Shaw AT. Targeting
ALK: Precision medicine takes on drug resistance. Cancer Discov.
7:137–155. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Felip E, de Braud FG, Maur M, Loong HH,
Shaw AT, Vansteenkiste JF, John T, Liu G, Lolkema MP, Selvaggi G,
et al: Ceritinib plus nivolumab in patients with advanced
ALK-rearranged non-small cell lung cancer: Results of an
open-label, multicenter, phase 1b study. J Thorac Oncol.
15:392–403. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jiang K, Wang J, Liu J, Ward T, Wordeman
L, Davidson A, Wang F and Yao X: TIP150 interacts with and targets
MCAK at the microtubule plus ends. EMBO Rep. 10:857–865. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pongor L, Kormos M, Hatzis C, Pusztai L,
Szabó A and Győrffy B: A genome-wide approach to link genotype to
clinical outcome by utilizing next generation sequencing and gene
chip data of 6,697 breast cancer patients. Genome Med. 7:1042015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xicota L, Cosentino S, Vardarajan B,
Mayeux R, Perls TT, Andersen SL, Zmuda JM, Thyagarajan B, Yashin A,
Wojczynski MK, et al: Whole genome-wide sequence analysis of
long-lived families (long-life family study) identifies MTUS2 gene
associated with late-onset Alzheimer's disease. Alzheimers Dement.
20:2670–2679. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu M, Liu X, Suo P, Gong Y, Qu B, Peng X,
Xiao W, Li Y, Chen Y, Zeng Z, et al: The contribution of hereditary
cancer-related germline mutations to lung cancer susceptibility.
Transl Lung Cancer Res. 9:646–658. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ricciuti B, Elkrief A, Alessi J, Wang X,
Li Y, Gupta H, Muldoon DM, Bertram AA, Pecci F, Lamberti G, et al:
Clinicopathologic, genomic, and immunophenotypic landscape of ATM
mutations in non-small cell lung cancer. Clin Cancer Res.
29:2540–2550. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ferrari SM, Ragusa F, Elia G, Mazzi V,
Balestri E, Botrini C, Rugani L, Patrizio A, Piaggi S, La Motta C,
et al: Antineoplastic effect of ALK inhibitor crizotinib in primary
human anaplastic thyroid cancer cells with STRN-ALK fusion in
vitro. Int J Mol Sci. 25:67342024. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lui K, Cheung KK, Ng WW, Wang Y, Au DWH
and Cho WC: The impact of genetic mutations on the efficacy of
immunotherapies in lung cancer. Int J Mol Sci. 25:119542024.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ren H, Hou X, Eiken PW, Zhang J, Pierson
KE, Nair AA, Davila JI, Kovarikova H, Jang JS, Johnson SH, et al:
Identification and development of a lung adenocarcinoma PDX model
with STRN-ALK fusion. Clin Lung Cancer. 20:e142–e147. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li M, An Z, Tang Q, Ma Y, Yan J, Chen S
and Wang Y: Mixed responses to first-line alectinib in non-small
cell lung cancer patients with rare ALK gene fusions: A case series
and literature review. J Cell Mol Med. 25:9476–9481. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nagasaka M, Sarvadevabatla N, Iwata S, Ge
Y, Sukari A, Klosowski C and Yanagihara R: STRN-ALK, A novel
in-frame fusion with response to alectinib. JTO Clin Res Rep.
2:1001252020.PubMed/NCBI
|
|
20
|
Nakanishi Y, Masuda S, Iida Y, Takahashi N
and Hashimoto S: Case report of non-small cell lung cancer with
STRN-ALK translocation: A nonresponder to alectinib. J Thorac
Oncol. 12:e202–e204. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Song GQ, Li YZ, Kong W and Hu GQ: Case
Report: A rare case of non-small cell lung cancer with STRN-ALK
fusion in a patient in very poor condition treated with first-line
ensartinib. Front Oncol. 13:12356792023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Su C, Jiang Y, Jiang W, Wang H, Liu S,
Shao Y, Zhao W, Ning R and Yu Q: STRN-ALK fusion in lung
adenocarcinoma with excellent response upon alectinib treatment: A
case report and literature review. Onco Targets Ther.
13:12515–12519. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sun K, Nie L, Nong L and Cheng Y: Primary
resistance to alectinib in a patient with STRN-ALK-positive
non-small cell lung cancer: A case report. Thorac Cancer.
12:1927–1930. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang Y, Qin SK, Zhu J, Wang R, Li YM, Xie
ZY and Wu Q: A rare STRN-ALK fusion in lung adenocarcinoma
identified using next-generation sequencing-based circulating tumor
DNA profiling exhibits excellent response to crizotinib. Mayo Clin
Proc Innov Qual Outcomes. 1:111–116. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zeng H, Li Y, Wang Y, Huang M, Zhang Y,
Tian P and Li W: Case report: Identification of two rare fusions,
PDK1-ALK and STRN-ALK, that coexist in a lung adenocarcinoma
patient and the response to alectinib. Front Oncol. 11:7228432021.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zeng Q, Gao H, Zhang L, Qin S, Gu Y and
Chen Q: Coexistence of a secondary STRN-ALK, EML4-ALK double-fusion
variant in a lung adenocarcinoma patient with EGFR mutation: A case
report. Anticancer Drugs. 32:890–893. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou C, Zeng L, Zhang Y and Yang N:
Responder of gefitinib plus crizotinib in osimertinib failure
EGFR-mutant NSCLC-resistant with newly identified STRN-ALK by
next-generation sequencing. J Thorac Oncol. 14:e143–e144. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Peters S, Camidge DR, Shaw AT, Gadgeel S,
Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, et al:
Alectinib versus crizotinib in untreated ALK-positive
non-small-cell lung cancer. N Engl J Med. 377:829–838. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhou C, Kim SW, Reungwetwattana T, Zhou J,
Zhang Y, He J, Yang JJ, Cheng Y, Lee SH, Bu L, et al: Alectinib
versus crizotinib in untreated Asian patients with anaplastic
lymphoma kinase-positive non-small-cell lung cancer (ALESIA): A
randomised phase 3 study. Lancet Respir Med. 7:437–446. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Su C, Zhou J, Qiang H, Zhao J, Chang Q, Ji
X, Li J, Xie M and Chu T: Special issue ‘The advance of solid tumor
research in China’: Real-world clinical outcomes of alectinib for
advanced nonsmall-cell lung cancer patients with ALK fusion in
China. Int J Cancer. 152:15–23. 2023. View Article : Google Scholar : PubMed/NCBI
|
